Obesity Facts最新文献

{"title":"High Prevalence and Overlap of Neurodevelopmental Problems in Children with Obesity.","authors":"Maria Dellenmark-Blom, Kajsa Järvholm, Lovisa Sjögren, Anna Levinsson, Anna Björk, Jovanna Dahlgren","doi":"10.1159/000552403","DOIUrl":"10.1159/000552403","url":null,"abstract":"<p><strong>Introduction: </strong>The aim was to identify neurodevelopmental diagnoses and problems and the extent of their overlap in children undergoing obesity treatment.</p><p><strong>Methods: </strong>Totally, 139 children (72 girls; mean age 12.7 years, mean BMI SDS 3.1) were recruited from three obesity clinics in Sweden. Motor, executive, perception, memory, language, learning, social, and emotional/behavioural functioning were assessed with an age-normed questionnaire. Scores ≥ the 90th percentile were considered indicative of problems with probable clinical relevance in each domain. Neurodevelopmental diagnoses were subsequently collected from the patients' records. The proportion of children exceeding the clinical threshold in each domain was compared with the expected population frequency (10%) and between participants with and without neurodevelopmental disorders.</p><p><strong>Results: </strong>The proportion exceeding the 90th percentile was significantly higher than the expected 10% in all domains: ranging from 33.6% (memory functioning) to 54.0% (emotional/behavioral functioning) (p < 0.001). Neurodevelopmental disorders were diagnosed in 52.5% (73/139). Diagnosed children had higher rates and greater overlap of neurodevelopmental problems than children without diagnoses (p < 0.001).</p><p><strong>Conclusion: </strong>Recognizing neurodevelopmental problems in children with obesity may improve understanding of their needs in obesity treatment settings.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-13"},"PeriodicalIF":4.1,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13336804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Management and Healthcare Utilization among Adults with Overweight and Obesity in Germany: A Representative Survey of General Practitioner Consultations and Digital and Pharmacological Treatment Options.","authors":"Laura Kudlek, Hannah Z Hennig, Hannah Haumann, Falko F Sniehotta","doi":"10.1159/000552226","DOIUrl":"10.1159/000552226","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity prevalence is high, requiring effective and scalable treatment options. German guidelines recommend referral to multimodal treatment programmes. However, reimbursement by statutory health insurance remains fragmented. Little is known about how people with overweight and obesity engage with available support in Germany.</p><p><strong>Methods: </strong>An online survey was administered to a representative sample of adults living with overweight or obesity in Germany. Participants reported awareness, use, interest, and perceived barriers regarding uptake of (a) primary care consultations, (b) behavioural programmes, and (c) pharmacotherapy for obesity.</p><p><strong>Results: </strong>A total of 2,065 respondents (46.5% women; 53.3% with overweight; 46.7% with obesity) were included. Most had experience with weight management (85.5%), but approaches were predominantly self-directed (75.1%). Engagement with professional obesity care was limited (conversations with general practitioners: 43.1%; participation in structured behavioural weight management programme: 7.8%; use of pharmacotherapy: 6.2%). Awareness and interest varied across treatment modalities, with particularly low awareness (19.6%) but high interest (39.1%) in behavioural programmes. Common barriers included lack of awareness, concerns about long-term effectiveness and side effects, and perception that support was not yet necessary.</p><p><strong>Conclusion: </strong>We identify a substantial evidence-practice gap in German obesity care, characterized by low reported use of professional support despite widespread weight management attempts. Beyond improving access and availability of services, effective obesity care also requires better communication on the effectiveness of evidence-based treatments, in particular behavioural programmes. Additionally, promoting a long-term, chronic-disease model of obesity and weight management may help align expectations, reduce discontinuation, and support sustained engagement with care.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-13"},"PeriodicalIF":4.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Threshold: Nonlinear Impact of Body Mass Index on Pulmonary Function in Severe Obesity.","authors":"Yuntao Nie, Shan Zheng, Zekai Zhou, Baoyin Liu, Hua Meng","doi":"10.1159/000552246","DOIUrl":"10.1159/000552246","url":null,"abstract":"<p><strong>Introduction: </strong>The conflicting impact of obesity on pulmonary function has been observed. Our study aimed at exploring the relationship between body mass index (BMI) and pulmonary function parameters in individuals with obesity.</p><p><strong>Methods: </strong>This cross-sectional study included a consecutive cohort of bariatric surgery candidates with pulmonary function tests. BMI, analyzed as both quartile-stratified groups and a continuous variable, was evaluated for associations with pulmonary function parameters and the risk of pulmonary impairment.</p><p><strong>Results: </strong>A total of 1,834 patients with obesity (BMI range: 27.5-76.4 kg/m2) were included in our study. BMI exhibited a significantly positive correlation with forced vital capacity (FVC), forced expiratory volume in 1 s (FEV₁), total lung capacity, and functional residual capacity (p < 0.001), and a negative correlation with FVC percent predicted (FVC % pred), FEV₁ percent predicted (FEV₁ % pred), FEV₁/FVC%, and residual volume/TLC (p < 0.05). Nonlinear relationships were found between BMI and both FVC % pred and FEV₁ % pred (P for nonlinearity <0.01) after adjusting for covariables. Beyond the threshold BMI of 38.2 kg/m2, FVC % pred and FEV₁ % pred declined significantly (FVC % pred: β = -0.522, 95% CI: -0.756 to -0.289; FEV₁ % pred: β = -0.435, 95% CI: -0.869 to -0.199), and the risk of pulmonary function impairment increased (OR = 1.008, 95% CI: 1.002-1.014).</p><p><strong>Conclusion: </strong>BMI exhibited a nonlinear relationship with pulmonary function parameters. Beyond the critical threshold of 38.2 kg/m2, increasing BMI led to a significant decline in ventilatory capacity, concomitant with an amplified risk of pulmonary function impairment.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-12"},"PeriodicalIF":4.1,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.","authors":"Sema Hepşen, Cem Haymana, Gizem Ertepe Küçükgöde, Büşra Özcan, Burak Özbaş, Arzu Or Koca, Berna İmge Aydoğan, Çiğdem Tura Bahadır, Emre Durcan, Volkan Yumuk, Bora Toros, Ziynet Alphan Üç, Çağatay Emir Önder, Zuhal Karaca Karagöz, Mehmet Aşık, Yusuf Öztürk, Muhammet Kocabaş, Melia Karaköse, Hayri Bostan, Sinem Kıyıcı, Serpil Salman, Dilek Gogas Yavuz, Yağmur Göksoy Solak, Osman Onur Daloğlu, Mehmet Ali Eren, Şahin Doğanay, Mehmet Güven, Gizem Ilgın Kaplan, Mustafa Cesur, Eda Demir Önal, Sibel Ertek Yalçın, Kemal Ağbaht, Elif Melis Baloğlu Akyol, Selin Genç, Özge Özer, Yasin Şimşek, Ömercan Topaloğlu, Fettah Acıbucu, Mehmet Emin Bozdoğan, Barış Karagün, Rıfat Emral, Sinem Başak Tan, Yahya Erdem İnce, Gamze Akkuş, Güven Barış Cansu, Mehmet Akif Saltabaş, Bekir Çakır, Gülsüm Karaahmetli, Samet Alkan, Mustafa Demirpençe, Işılay Taşkaldıran, Seher Tanrıkulu, Emre Bozkırlı, Seda Turgut, Didem Dereli Akdeniz, Arif Cengiz Gültekin, Ethem Turgay Cerit, Tülay Omma, Bülent Can, Hüseyin Soylu, Yusuf Emre Uzun, Süleyman Hilmi İpekçi, Özge Telci Çaklılı, Mehmet Çağrı Ünal, Gülşah Elbüken, Buket Büşra İçin, Yusuf Kır, Adnan Batman, Sedat Can Güney, Banu Ertürk, Pınar Akhanlı, Merve Çatak, Ayşe Kargılı Çarlıoğlu, Sakine Güzel Esen, Hakan Doğruel, İsmail Yıldız, Kübra Özsoy, İbrahim Demirci, Erman Çakal, Fahri Bayram, Alper Sönmez","doi":"10.1159/000552104","DOIUrl":"10.1159/000552104","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments.</p><p><strong>Methods: </strong>This study included 2,549 patients with obesity treated with semaglutide (n = 1,434) or tirzepatide (n = 1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM).</p><p><strong>Results: </strong>At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p = 0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p = 0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM.</p><p><strong>Conclusion: </strong>In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-17"},"PeriodicalIF":4.1,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Diabetes Remission and Relapse following Sleeve Gastrectomy and Gastric Bypass: A 2- and 5-Year Follow-Up Study.","authors":"Beatrice Leyaro, Lyz Howie, Abdulmajid Ali, Raymond Carragher","doi":"10.1159/000552002","DOIUrl":"10.1159/000552002","url":null,"abstract":"<p><strong>Introduction: </strong>Bariatric surgery is an established treatment for obesity and has been shown to improve glycaemic control and frequently induces remission of type 2 diabetes mellitus (T2DM). However, the long-term sustainability of remission remains uncertain as relapse may occur over time. This study evaluated short- and long-term remission rates and identified factors associated with remission durability and relapse.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted, which included 186 patients with obesity and type2 diabetes who underwent sleeve gastrectomy (SG) or Roux-en-Y gastric bypass between January 2009 and December 2020 at University Hospital Ayr. Diabetes remission was defined as HbA1c <6.0% without anti-diabetic medication use, assessed at 2 years (short term) and 5 years (long term). Multivariable logistic and Cox regression models were used to identify factors associated with remission and relapse.</p><p><strong>Results: </strong>Two- and 5-year post-surgery remission rates were 57.5% and 36.4%, respectively. Shorter duration of diabetes (OR 0.86, 95% CI 0.76-0.96; p = 0.009), lower preoperative HbA1c (OR 0.61, 95% CI 0.43-0.87; p = 0.005), and not using anti-diabetic medications before surgery (p < 0.05) were all associated with a higher likelihood of diabetes remission at 2 years. Of 107 patients who achieved remission at 2 years, 33.4% experienced diabetes relapse by 5 years. Age (HR 1.06; 95% CI 1.01-1.12; p < 0.015) and use of anti-diabetic medications (p < 0.05) were identified as significant factors associated with diabetes relapse.</p><p><strong>Conclusion: </strong>Bariatric surgery is effective in achieving early remission of T2DM; however, one-third of patients experience relapse within 5 years. A more favourable preoperative metabolic profile and younger age play a crucial role in remission durability. These findings highlight the importance of long-term follow-up and individualised patient counselling on expected diabetes outcomes after bariatric surgery.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-15"},"PeriodicalIF":4.1,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esophageal Perforation during Bougie Calibration: Are Bariatric Surgeons Still Haunted by the Bo(u)gie Man?","authors":"Panagiotis Lainas, Maurizio De Luca, Roxanna Zakeri, Evangelos Menenakos, Amanda Belluzzi","doi":"10.1159/000552003","DOIUrl":"10.1159/000552003","url":null,"abstract":"","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-4"},"PeriodicalIF":4.1,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13293609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report.","authors":"Eline E P L van der Walle, Mariëtte R Boon, Elisabeth F C van Rossum, Erica L T van den Akker","doi":"10.1159/000551729","DOIUrl":"10.1159/000551729","url":null,"abstract":"<p><strong>Introduction: </strong>Tirzepatide, a dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, is recently approved for the treatment of type 2 diabetes and obesity in adults. Melanocortin-4-receptor (MC4R) deficiency is the most common monogenic cause of obesity and presents with hyperphagia and early onset obesity. While tirzepatide seems to be effective in inducing weight loss in adults with MC4R deficiency, its effects on hyperphagia and weight loss in pediatric patients are unexplored.</p><p><strong>Case presentation: </strong>A 17-year-old girl was admitted to our specialized obesity clinic because of hyperphagia and severe early onset obesity due to MC4R deficiency. She had an extensive history of lifestyle interventions and psychological support and maintained a high level of physical activity. Despite these efforts, she presented with a BMI of 37 kg/m2 (3.68 SDS) and a substantial psychosocial burden. Vital signs and laboratory evaluations revealed no obesity-related complications. Tirzepatide was initiated at a dose of 2.5 mg weekly and slowly titrated to a maximum dose of 12.5 mg weekly. She initially experienced a substantial reduction in hyperphagia and reported less food noise, a reduction in hunger feelings and prolonged postprandial satiety. However, after 12 weeks hunger scores started to increase again, approaching pre-treatment levels at 28 weeks of follow-up. Metformin was added at 28 weeks in an attempt to better manage of hyperphagia, resulting in a reduction in hyperphagia. Despite these increasing hunger feelings from week 12 to 28, substantial weight loss was achieved, and the patient lost -13.9% of her initial body weight at 28 weeks. After addition of metformin, the patient lost an additional -7% of her weight. Total body weight reduction at week 37 was -20.9%. Tirzepatide was well tolerated, with no adverse effects reported at 41 weeks of follow-up.</p><p><strong>Conclusion: </strong>This case report suggests that tirzepatide is effective in reducing body weight in adolescents with MC4R deficiency. However, the question remains what the effect is on hunger and satiety in the long run and at a higher dose. Cohort studies are needed to assess long-term safety and effectiveness of tirzepatide in the pediatric population and in managing hyperphagia.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-7"},"PeriodicalIF":4.1,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italy's Landmark Obesity Law: The Long Road from Science to Policy.","authors":"Michele O Carruba, Andrea Lenzi, Pietro Paganini, Federico Serra, Enzo Nisoli","doi":"10.1159/000551505","DOIUrl":"10.1159/000551505","url":null,"abstract":"","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-7"},"PeriodicalIF":4.1,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13252980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Improvements with Setmelanotide in a 2-Year-Old Patient with Hyperphagia and Obesity due to Leptin Receptor Deficiency: A Case Report.","authors":"Mónica Ruiz Pons, Marina Gutierrez Vilar, Alejandra Pérez Rodriguez, Javier Merino Alonso","doi":"10.1159/000551601","DOIUrl":"10.1159/000551601","url":null,"abstract":"<p><strong>Introduction: </strong>Dysregulation of the melanocortin-4 receptor (MC4R) pathway can lead to hyperphagia and early-onset obesity. Setmelanotide, an MC4R agonist, is approved for patients age ≥2 years with rare MC4R pathway disease due to Bardet-Biedl syndrome, pro-opiomelanocortin or proprotein convertase subtilisin/kexin type 1 deficiency, or leptin receptor (LEPR) deficiency, but there are limited clinical data on treatment outcomes in very young children. This case report describes the use of setmelanotide in a 2-year-old child with hyperphagia and obesity due to LEPR deficiency.</p><p><strong>Case description: </strong>The patient presented with early-onset hyperphagia, rapid weight gain, and obesity-associated delays in motor development. Following a medical assessment in May 2021, he was diagnosed with LEPR deficiency. Setmelanotide treatment via subcutaneous injection was initiated in March 2023 (patient age 2 years 4 months) at a dose of 0.5 mg/day, increased to 2.5 mg/day in 0.5 mg increments, and the patient was followed for 23 months. Following treatment initiation, significant clinical improvements were observed, including reductions in hyperphagia, food intake and cravings, and body mass index (BMI). Motor skill function also improved, with the child achieving milestones such as crawling and kneeling. Significant improvements in caregivers' QoL were also reported. Reported adverse events included skin rash and skin hyperpigmentation.</p><p><strong>Conclusion: </strong>Setmelanotide treatment started in a 2-year-old patient and continued for 23 months led to improvements in hyperphagia, BMI, and blood lipids and led to significant improvements in caregivers' QoL. Improved motor skill function was also seen with as BMI decreased. These findings support the use of setmelanotide in young children with hyperphagia and obesity due to LEPR deficiency.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-8"},"PeriodicalIF":4.1,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13249433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147531343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association between the Obesogenic Environment and BMI Independent of Familial Factors: A Cross-Sectional Twin Study.","authors":"Bram J Berntzen, Joline W J Beulens, Jeroen Lakerveld","doi":"10.1159/000551733","DOIUrl":"10.1159/000551733","url":null,"abstract":"<p><strong>Introduction: </strong>To investigate the association between the obesogenic environment and body mass index (BMI), independent of familial factors shared by twins (e.g., genetic and early life environmental factors).</p><p><strong>Methods: </strong>This cross-sectional twin study included 2,764 adults (77% female, 72% monozygotic [MZ], mean age 40 [SD 14]) from the Dutch Twin Registry. The Obesogenic Built Environment CharacterisTics (OBCT) index was used as neighborhood \"obesogenic\" exposure, integrating food-environment healthiness, walkability, drivability, and sports facilities within a 1,000 m Euclidean buffer around the residential address. Univariate twin models established the heritability estimates of the OBCT-index and BMI. Full-informed maximum likelihood linear regressions determined individual and pairwise difference (i.e., within-twin-pair differences in outcome and exposure) associations between the OBCT-index and BMI.</p><p><strong>Results: </strong>The heritability of the OBCT-index was 9% and common environmental factors explained 27% of its variation, whereas the BMI heritability was 75%. Living in a 10% higher OBCT-index environment was associated with a mean [95% CI] 0.15 [0.07, 0.24] kg/m2 higher BMI in all twin individuals. However, this association was nonsignificant in the MZ and same-sex DZ twin pairwise difference analyses.</p><p><strong>Conclusion: </strong>This study found a small association between a more obesogenic environment and a higher BMI, yet the association was explained by familial confounding. Future research in larger, more environmentally diverse international twin cohorts is needed to elucidate gene-environment interactions.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-12"},"PeriodicalIF":4.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13241167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}